Late last Friday, drug maker AstraZeneca PLC (NYSE: AZN) lost its court fight to prevent a generic version of its anti-psychotic drug Seroquel from reaching the US market. The company had sought to keep the generic, quetiapine fumarate, off the market until December of this year.
AstraZeneca wanted the FDA to delay the introduction of the generic because the company had “marketing exclusivity periods” for the language on the label of its Seroquel products that did not end until December. The FDA denied the request, the company sued, and the federal court sided with the FDA. AstraZeneca said in a press release this morning that it is “evaluating its options.”
The company’s patent protection on Seroquel ends today. The company posted revenue of $5.83 billion on sales of Seroquel in 2011. Between now and 2016, AstraZeneca loses patent protection on three more of its best-sellers, Atacand, Nexium, and Crestor.
Shares are down -0.66% in the pre-market at $44.88 in a 52-week range of $40.89-$52.54.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
